Phosphaplatin liquid formulations
Pharmaceutical compositions of phosphaplatin compounds, in particular buffered stable liquid formulations of pyrodach-2 ready for use in the treatment of various cancers, and methods of preparation are disclosed.
1. A liquid pharmaceutical composition comprising a phosphaplatin compound of formula (I) or (II), or a pharmaceutically acceptable salt thereof, and an aqueous buffer solution having pH at about or above 7:
wherein R 1 and R 2 are each independently selected from the group consisting of substituted or unsubstituted aliphatic amines and substituted or unsubstituted aromatic amines; R 3 is selected from the group consisting of substituted or unsubstituted aliphatic 1,2-diamines and substituted or unsubstituted aromatic 1,2-diamines; and wherein the buffer solution comprises a pyrophosphate salt to stabilize the phosphaplatin compound, and the liquid pharmaceutical composition is a ready-to-use liquid formulation suitable for parenteral administration.
2. The liquid pharmaceutical composition of claim 1 , wherein concentration of the phosphaplatin compound is about 20 mg/mL or less.
3. The liquid pharmaceutical composition of claim 2 , wherein the concentration of the phosphaplatin compound is about 5 mg/mL.
4. The liquid pharmaceutical composition of claim 1 , wherein the buffer comprises a sodium or potassium salt of phosphate or bicarbonate/carbonate.
5. The liquid pharmaceutical composition of claim 4 , wherein the buffer salt concentration is between about 1 mM and about 100 mM.
6. The liquid pharmaceutical composition of claim 1 , wherein the pH is in the range of about 7.0 to about 9.0.
7. The liquid pharmaceutical composition of claim 6 , wherein the buffer is potassium phosphate; the concentration of the phosphaplatin compound is about 5 mg/mL and the pH is between about 7.0 and about 8.0.
8. The liquid pharmaceutical composition of claim 7 , wherein the buffer concentration is about 10 mM.
9. The liquid pharmaceutical composition of claim 1 , wherein the pyrophosphate salt is sodium pyrophosphate.
10. The liquid pharmaceutical composition of claim 9 , wherein the molar ratio of pyrophosphate anion to the phosphaplatin compound is at least about 0.1 to about 1.
11. The liquid pharmaceutical composition of claim 9 , wherein the concentration of the phosphaplatin compound is about 5 mg/mL, the pyrophosphate concentration is about 5.2 mM, and the pH is in the range of about 7.0 to about 8.0.
12. The liquid pharmaceutical composition of claim 1 , wherein the phosphaplatin compound is a trans-1,2-cyclohexanediamine-(dihydrogen pyrophosphato)platinum(II) (“trans-pyrodach-2”) complex.
13. The liquid pharmaceutical composition of claim 1 , wherein the phosphaplatin compound is (R,R)-trans-1,2-cyclohexanediamine-(dihydrogen pyrophosphato)platinum(II) (“(R,R)-trans-pyrodach-2”).
14. The liquid pharmaceutical composition of claim 1 , wherein the phosphaplatin compound is (S,S)-trans-1,2-cyclohexanediamine-(dihydrogen pyrophosphato)platinum(II) (“(S,S)-trans-pyrodach-2”).
15. The liquid pharmaceutical composition of claim 1 , wherein the phosphaplatin compound is cis-1,2-cyclohexanediamine-(dihydrogen pyrophosphato)-platinum(II) (“cis-pyrodach-2”).
16. A method of treating a cancer selected from the group consisting of gynecological cancers, genitourinary cancers, lung cancers, head-and-neck cancers, skin cancers, gastrointestinal cancers, breast cancers, bone and chondroital cancers, and hematological cancers the method comprising administering to a subject in need thereof a therapeutically effectively amount of the liquid pharmaceutical composition of claim 1 .
17. A process of preparing a liquid pharmaceutical composition of phosphaplatin compound according to claim 1 , the process comprising: a) dissolving a phosphaplatin compound in an aqueous buffer to obtain a solution comprising a sufficient amount of hydroxide base such that the pH remains at or above 7; b) adding a pyrophosphate salt to the solution to stabilize the phosphaplatin compound; c) optionally adding a hydroxide base to adjust the pH to a desired range; and d) filtering the solution to obtain a liquid formulation under sterile conditions, wherein the aqueous buffer is a phosphate buffer, a carbonate/bicarbonate buffer, or a combination thereof.
18. The process of claim 17 , wherein the pH of the liquid formulation is in the range of about 7.0 to about 9.0.
19. The process of claim 17 , wherein the pyrophosphate salt is sodium pyrophosphate.
20. The process of claim 17 , further comprising d) filling the solution into a vial, stoppering and capping the vial in a sterile environment so that the formulation is ready for use.